Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 21, 2022
Event Date: December 21, 2022 (Agreement); December 22, 2022 (Closing)
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement to raise capital through a Regulation S private placement. The transaction closed on December 22, 2022.
Key Financial Metrics and Transaction Details
Capital Raised: The Company expects to receive aggregate gross proceeds of $220,585 before deducting placement agent fees and transaction expenses.
Securities Issued:
- Series D Convertible Preferred Stock: 176,462 shares issued at $1.25 per Unit.
- Warrants: 529,386 warrants issued, each exercisable for one share of Common Stock at an initial price of $0.29.
Management Participation: Approximately 15.10% of funds were secured from senior management, including CFO Spiro Sakiris ($19,991.25) and Director of Global Integration Manuel Kostandas ($13,327.50).
Placement Agent Fees: Winx Capital Pty Ltd. was engaged for a fixed fee of AU$20,000 plus 6% of gross proceeds, plus warrants to purchase up to 26,469 shares of Common Stock at $0.52 per share.
Material Changes and Terms
Conversion Rights: The Series D Preferred Stock is convertible into an aggregate of 529,386 shares of Common Stock following shareholder approval. No additional consideration is required for conversion.
Voting Rights: The Preferred Stock generally has no voting rights except as required by law or regarding a "Reverse Stock Split." In such cases, each share of Preferred Stock carries 20,000 votes.
Warrant Terms: Warrants are exercisable six months following issuance and expire five years after the initial exercise date. The exercise price is subject to adjustment for stock splits or dividends.
Use of Proceeds: Net proceeds are intended for general working capital purposes.
Guidance, Risks, and Contingencies
Contingencies: The conversion of Preferred Stock into Common Stock is contingent upon shareholder approval. If approval is not received, the Preferred Stock will remain outstanding and will not convert.
Risks: The filing notes that the Purchase Agreement representations are made solely for the benefit of the contracting parties and should be read in conjunction with periodic reports. The transaction involves unregistered sales of equity securities exempt under Section 4(a)(2) and Regulation S.
Outlook: No specific financial guidance or revenue outlook was provided in this filing; the focus is on liquidity enhancement via the private placement.
Investor Verification Checklist
- Verify the status of the shareholder vote required to convert the Series D Preferred Stock into Common Stock.
- Confirm the final net proceeds after deducting the 6% placement agent fee and other transaction expenses.
- Review the impact of the 529,386 new shares (upon conversion) and 529,386 warrant shares on existing shareholder dilution.
- Check for any subsequent filings regarding the registration rights granted to investors for the resale of underlying shares.
- Monitor the Company's cash burn rate to assess the sufficiency of the $220,585 gross proceeds for stated working capital needs.